Martin P, Bugat R, Pinon G, Pinel M C, Heritier F, Chazard M, Delestrain M C, Belpomme D
Association for Therapeutic Cancer Research, Avignon, France.
Cancer Chemother Pharmacol. 1989;23(5):331-2. doi: 10.1007/BF00292415.
Carboplatin (Cb) is an active drug in ovarian carcinoma that has fewer visceral side effects than cisplatin (CDDP) but higher myelotoxicity, which makes it difficult to combine at efficient doses with other myelotoxic drugs. In a preliminary study in advanced ovarian carcinoma, Rosso et al. showed the maximum tolerated dose of Cb given in combination with cyclophosphamide (C) and adriamycin (A) to be 200 mg/m2. Since the efficacy of Cb may be dose-dependent, as is that of CDDP, we started a feasibility study of a CACb-300 regimen, that is, using Cb at 300 mg/m2 with lower C and A doses. Our data shows that the CACb-300 combination can safely be given in previously untreated patients for at least six 28-day cycles.
卡铂（Cb）是一种对卵巢癌有效的药物，与顺铂（CDDP）相比，其内脏副作用较少，但骨髓毒性较高，这使得它难以与其他骨髓毒性药物以有效剂量联合使用。在一项针对晚期卵巢癌的初步研究中，罗索等人表明，Cb与环磷酰胺（C）和阿霉素（A）联合使用时的最大耐受剂量为200mg/m²。由于Cb的疗效可能与CDDP一样存在剂量依赖性，我们启动了一项关于CACb - 300方案的可行性研究，即使用300mg/m²的Cb并降低C和A的剂量。我们的数据表明，CACb - 300联合方案可以安全地用于未经治疗的患者，至少进行六个28天周期的治疗。
